Présentation de l'entreprise
Allurion Technologies Inc. operates within the healthcare sector, specifically focusing on the medical devices industry to provide solutions for weight management. The company's core business involves ending obesity through a specialized weight loss platform designed to treat individuals who are overweight, utilizing its proprietary Allurion Program. This platform features a swallowable, procedure-less intragastric balloon intended for weight loss, complemented by access to artificial intelligence-powered remote patient monitoring. As of the latest reporting period, the company's market capitalization stands at $12.00M, with annualized revenue reaching $15.23M and a workforce of 38 employees. These financial figures indicate that Allurion Technologies Inc. operates as a small-cap entity with limited revenue generation relative to its specific niche in intragastric interventions. The combination of a modest market cap and single-digit employee count suggests a highly specialized operational scale typical of early-stage medical device developers focusing on proprietary technology deployment.
Santé financière
The company reported revenue of $15.23M over the trailing twelve months, yet this generated a net income of -$28,755,000, highlighting a significant divergence between top-line sales and bottom-line profitability. Additionally, EBITDA stands at -$29,174,000, revealing that the gap between revenue and these profit metrics underscores a cost structure where operating expenses and losses substantially exceed gross profits. Free cash flow is negative at -$16,837,124, indicating that the company is consuming cash reserves rather than generating liquidity from its core operations. This negative cash flow position limits financial flexibility, requiring the company to rely on external capital sources to fund ongoing research, development, and operational burn. The gross margin is recorded at 62.8%, which suggests the company maintains pricing power or low cost of goods sold relative to sales, yet this does not translate to overall profitability. In contrast, the operating margin is -174.2% and the profit margin is -188.8%, figures that indicate severe inefficiencies or high fixed costs absorbing the majority of revenue before reaching the bottom line. On the balance sheet, cash holdings of $5.41M are significantly outweighed by total debt of $76.74M, creating a precarious liquidity environment. While the debt-to-equity ratio is listed as N/A due to the company's financial structure, the sheer volume of debt relative to cash implies a highly leveraged position. The current ratio is 0.33, which indicates that the company possesses only 33 cents in current assets for every dollar of current liabilities, signaling potential short-term liquidity constraints. Return on equity is N/A, while return on assets stands at -77.6%, metrics that reveal management is generating substantial losses on the capital base employed to run the business.
Évaluation de la valorisation
The trailing P/E ratio is N/A due to the lack of positive earnings, whereas the forward P/E is -0.65, implying that the market currently prices in continued losses rather than expecting immediate earnings normalization. The price-to-book ratio is -0.13, a negative figure that indicates the market values the company at a fraction below its book value or suggests accounting adjustments that have depressed the equity value significantly. The price-to-sales ratio is 0.79, suggesting the market is willing to pay 79 cents for every dollar of sales, which serves as a primary valuation anchor given the absence of a meaningful P/E metric. Furthermore, the EV/EBITDA multiple is -2.84, an alternative valuation metric that reflects the company's negative enterprise value components relative to its operating earnings before interest, taxes, depreciation, and amortization. The stock has traded within a 52-week range with a high of $3.42 and a low of $0.23, meaning the current price sits at the upper end of its recent trading history relative to the low. The beta value is -0.25, which is an anomalous negative figure indicating that the stock's price volatility moves inversely to the broader market rather than exhibiting standard positive correlation.
Growth & Income
Revenue growth year-over-year is -35.4%, demonstrating a contraction in top-line sales, while earnings growth year-over-year is N/A because the company is currently unprofitable. Since the company is not a dividend payer, the dividend yield is N/A and the payout ratio is 0.0%, reflecting a strategy where the company retains all earnings (or rather, all capital) to fund operations and growth initiatives rather than distributing income to shareholders. Given the absence of a dividend history and the negative earnings trajectory, the company reinvests its limited cash flow directly into product development and market expansion to attempt to reverse the revenue decline. The overall growth and income profile for Allurion Technologies Inc. is characterized by significant revenue contraction and an inability to generate positive returns on capital or distribute dividends to investors.